Key Points
- Verily, Alphabet’s “moonshot” health venture, is shutting its medical device division.
- Staff layoffs were announced, though the exact number of affected employees was not disclosed.
- The move follows Alphabet’s 2023 restructuring that cut 12,000 positions company‑wide.
- CEO Stephen Gillett highlighted achievements like the Dexcom G7 glucose monitor.
- The Stargazer VNRC platform screened 7,800 patients, advancing drug‑targeting research.
- Verily will now concentrate on precision health, data, and artificial intelligence.
- The medical device segment was not a profit driver but contributed valuable research.
- Alphabet is redirecting resources toward AI and data infrastructure across its businesses.
Background and Scope of Verily
Verily, an Alphabet subsidiary known for its ambitious “moonshot” projects, has pursued a range of cutting‑edge health initiatives, from connected diabetes therapies to robotic surgery. The organization positioned itself at the intersection of technology and medicine, aiming to transform patient care through innovative devices and data‑driven solutions.
Decision to Close the Medical Device Division
In a memo obtained by Business Insider, Verily announced the closure of its medical device division and the accompanying staff reductions. The statement from a company spokesperson read, “We have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” The memo did not disclose the specific number of employees affected by the layoffs.
Alphabet’s Wider Strategic Shift
The shutdown is part of a larger strategic realignment that Alphabet began in 2023. During that period, the parent company cut 12,000 positions across multiple divisions, reallocating resources to strengthen its artificial intelligence and data infrastructure capabilities. Verily’s move mirrors this broader emphasis on AI and data as core growth drivers for the conglomerate.
Notable Achievements Highlighted by Leadership
Despite the closure of the device division, Verily’s leadership emphasized the venture’s significant contributions to medical research and patient outcomes. CEO Stephen Gillett cited several milestones, including the launch of the Dexcom G7 continuous glucose monitor, a system designed to aid diabetes management, and the introduction of the Stargazer VNRC drug‑targeting platform, which screened 7,800 patients. These initiatives, Gillett noted, advanced patient care and medical research, underscoring Verily’s impact even if the device segment was not a profit center for Alphabet.
Future Direction for Verily
Looking ahead, Verily will pivot to focus on its “core mission” as defined by its leadership: precision health, data, and artificial intelligence. The shift signals a move away from manufacturing physical medical devices toward leveraging data analytics and AI to personalize health interventions and drive new insights in the biomedical field.
Implications and Outlook
The closure of the medical device division marks a notable transition for Verily, reflecting both Alphabet’s broader corporate strategy and the evolving landscape of health technology. While the layoffs represent a setback for staff directly involved in device development, the company’s continued emphasis on data‑centric health solutions suggests that Verily will remain an influential player in the precision health arena, albeit with a redefined operational focus.
Source: engadget.com